Galectin Therapeutics (GALT) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. CART
8. LLY
9. TSLA
10. AZN

Go back to Galectin Therapeutics (GALT) Misses Q3 EPS by 6c

Galectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update

November 9, 2015 8:00 AM EST

NORCROSS, Ga., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and nine months ended September 30, 2015 and provided a business update. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission.

Management commentary

"Galectin Therapeutics has never been in a better position advancing the development of our galectin-3 inhibitor in non-alcoholic... More